Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 7
2006 8
2007 7
2008 11
2009 10
2010 7
2011 14
2012 18
2013 18
2014 21
2015 13
2016 11
2017 12
2018 29
2019 59
2020 83
2021 90
2022 80
2023 55
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Results by year

Filters applied: . Clear all
Page 1
Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project.
Cocci A, Pezzoli M, Bianco F, Blefari F, Bove P, Cornud F, De Rienzo G, Destefanis P, Di Trapani D, Giacobbe A, Giovanessi L, Laganà A, Lughezzani G, Manenti G, Muto G, Patelli G, Pinzi N, Regusci S, Russo GI, Salamanca JIM, Salvi M, Silvestri L, Verweij F, Walser E, Bertolo RG, Iacovelli V, Bertaccini A, Marchiori D, Davila H, Ditonno P, Gontero P, Iapicca G, M De Reijke T, Ricapito V, Pellegrini P, Minervini A, Serni S, Sessa F. Cocci A, et al. Among authors: minervini a. Asian J Urol. 2024 Apr;11(2):271-279. doi: 10.1016/j.ajur.2023.07.001. Epub 2023 Jul 11. Asian J Urol. 2024. PMID: 38680587 Free PMC article.
Open versus Robot-Assisted Radical Cystectomy for the Treatment of pT4a Bladder Cancer: Comparison of Perioperative Outcomes.
Perri D, Rocco B, Sighinolfi MC, Bove P, Pastore AL, Volpe A, Minervini A, Antonelli A, Zaramella S, Galfano A, Cacciamani GE, Celia A, Dalpiaz O, Crivellaro S, Greco F, Pini G, Porreca A, Pacchetti A, Calcagnile T, Berti L, Buizza C, Mazzoleni F, Bozzini G. Perri D, et al. Among authors: minervini a. Cancers (Basel). 2024 Mar 28;16(7):1329. doi: 10.3390/cancers16071329. Cancers (Basel). 2024. PMID: 38611006 Free PMC article.
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy.
Meagher MF, Minervini A, Mir MC, Cerrato C, Rebez G, Autorino R, Hampton L, Campi R, Kriegmair M, Linares E, Hevia V, Musquera M, D'Anna M, Roussel E, Albersen M, Pavan N, Claps F, Antonelli A, Marchioni M, Paksoy N, Erdem S, Derweesh IH. Meagher MF, et al. Among authors: minervini a. Eur Urol Open Sci. 2024 Mar 25;63:71-80. doi: 10.1016/j.euros.2024.02.001. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38572300 Free PMC article.
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B; CLIPOLY Study Group Collaborators. von Deimling M, et al. Among authors: minervini a. BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319. Online ahead of print. BJU Int. 2024. PMID: 38470089 Free article.
The prognostic role of histomorphological subtyping in nonmetastatic papillary renal cell carcinoma after curative surgery: is subtype really irrelevant? A propensity score matching analysis of a multi-institutional real life data.
Erdem S, Bertolo R, Campi R, Capitanio U, Amparore D, Anceschi U, Mir MC, Roussel E, Pavan N, Carbonara U, Kara O, Klatte T, Marchioni M, Pecoraro A, Muselaers S, Marandino L, Diana P, Borregales L, Palumbo C, Warren H, Wu Z, Calio A, Ciccarese C, Degirmenci E, Aydin R, Rebez G, Schips L, Simone G, Minervini A, Serni S, Ozcan F. Erdem S, et al. Among authors: minervini a. Urol Oncol. 2024 May;42(5):163.e1-163.e13. doi: 10.1016/j.urolonc.2024.01.028. Epub 2024 Mar 5. Urol Oncol. 2024. PMID: 38443238
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database.
Porreca A, Di Nicola M, Lucarelli G, Dorin VM, Soria F, Terracciano D, Mistretta FA, Luzzago S, Buonerba C, Cantiello F, Mari A, Minervini A, Veccia A, Antonelli A, Musi G, Hurle R, Busetto GM, Del Giudice F, Ferretti S, Perdonà S, Prete PD, Porreca A, Bove P, Crisan N, Russo GI, Damiano R, Amparore D, Porpiglia F, Autorino R, Piccinelli M, Brescia A, Tătaru SO, Crocetto F, Giudice AL, de Cobelli O, Schips L, Ferro M, Marchioni M. Porreca A, et al. Among authors: minervini a. Urol Oncol. 2024 Mar;42(3):69.e17-69.e25. doi: 10.1016/j.urolonc.2024.01.001. Epub 2024 Feb 1. Urol Oncol. 2024. PMID: 38302296 Free article.
443 results